Oct.2025 02
Views: 135
Precision UVB Therapy: Astiland's 308 nm Excimer Treatment Device Now Available for Clinics
Introduction
Discover Astiland's 308 nm Excimer Therapy Device — delivering precise, safe, and effective UVB treatments for vitiligo, psoriasis, and other skin conditions with advanced dermatological technology.
Details
In response to growing demand for targeted dermatological solutions, Astiland is pleased to unveil its 308 nm Excimer Therapy Device, designed specifically for professional skin clinics and medical aesthetic providers. Built to deliver safe, efficient, and lesion-specific UVB treatment, this system brings a new level of control and flexibility to the excimer therapy space.

Market Context & Opportunity

The global dermatology excimer laser market is experiencing robust growth, with the 308 nm excimer segment widely adopted for conditions such as vitiligo, psoriasis, and atopic dermatitis. 

 Targeted UVB therapy is increasingly preferred due to its ability to treat lesions with minimal exposure to surrounding skin, reducing side effects and improving patient comfort.

In this environment, devices that combine precision, clinical-grade output, and workflow convenience stand out—particularly for dermatology clinics, medical spas, and skin treatment centers.

Product Overview & Working Principle

Astiland’s 308 nm Excimer Therapy Device uses a monochromatic UVB light source calibrated to a precise wavelength of 308 nm, allowing clinicians to deliver phototherapy only to the marked lesion area. Surrounding healthy skin remains largely unaffected, minimizing collateral exposure.



The system’s control logic adapts irradiation time and energy dose, balancing therapeutic effect and safety. With focal delivery and energy uniformity, the device supports repeatable treatments while reducing cumulative phototoxic risk.



Key Features & Advantages

Lesion-Selective Irradiation — High-precision UVB light limited to the target area, protecting surrounding tissue.
Adjustable Spot Size / Window Options — Enables flexibility for small patches or larger skin areas.
Compact & Clinic-Friendly Design — Ergonomic build intended for regular dermatology use.
Low Operating Cost — No consumables or gas refill requirement, which helps clinics minimize running expenses.
Proven Clinical Applicability — Ideal for treating vitiligo, psoriasis, eczema, and other inflammatory skin disorders.

Comparable devices, such as the handheld 308 nm excimer systems used by leading dermatology equipment providers, emphasize compact design, localized UVB delivery, and lower maintenance overhead. 

Applications in Clinical Practice

Pre-treatment Mapping
Clinicians can map lesion boundaries and plan treatment zones with precision, using the device’s targeting mechanism to optimize dose placement.

Treatment Delivery
During sessions, the device ensures consistent energy output over defined areas, minimizing over- or under-exposure. This is especially beneficial in anatomically delicate zones.

Follow-up and Monitoring
Because of its uniform delivery characteristics, clinicians can reliably compare progress across sessions, track repigmentation or lesion regression, and adjust protocols accordingly.

Adoption & Competitive Position

Astiland’s excimer solution is designed to integrate smoothly into dermatology clinics seeking reliable targeted phototherapy without the footprint or complexity of full-scale laser systems. Given the growth trajectory of the excimer therapy market and increasing preference for non-invasive skin treatments, this product positions Astiland as a credible supplier for advanced dermatology tools. 

The device also competes favorably with existing 308 nm systems by offering easier maintenance, no consumables, and potentially lower total cost of ownership.
REQUEST MORE DETAILS
Please fill out the form below and click the button to request more information about
Name
Email*
Phone
Machine For*
Own SPA/Clinic/Gym
Resale
Other
Message*
We use Cookie to improve your online experience. By continuing browsing this website, we assume you agree our use of Cookie.